Contrafect Corp (CFRX)

[Rolling inflaton]

Only potential problem with this drug is that it is too effective, kills too many bacteria immediately and bacteria debris can produce a cytokine storm. But management is well aware and designed the trial with this in mind: low dose in combination with SOC, it is only a matter of finding the optimal dose. Going to be a qualitative jump in antibiotic efficacy and likely to get accelerated approval if they got the dose right.